Accueil
»
Bourse
»
Actions Amsterdam
»

Consensus des Analystes Galapagos Genomics

Cotation du 20/10/2020 à 17h35 Galapagos Genomics +0,09% 111,800€

Objectif de cours au 20/10/2020

131,800 €
Potentiel de +18%
cours actuel 111,800€

Note médiane des 11 analystes

2,4
5 Vendre 4 Alléger 3 Conserver 2 Renforcer 1 Acheter

Evolution des recommandations

Recommandations 20/10/2019 20/01/2020 20/04/2020 20/07/2020 20/10/2020
Acheter 6 4 4 3 3
Renforcer 3 1 1 1 1
Conserver 3 7 7 7 7
Alléger - - - - -
Vendre - - - - -
Nb d'analystes 12 12 12 11 11
Note Médiane 1,75 2,25 2,25 2,36 2,36
Historique des objectifs 172,454€ 181,818€ 195,090€ 195,000€ 131,800€

Prévisions

2019 2020 2021
Chiffre d'affaires 895,60 549,48 550,86
EBITDA 382,74 -178,41 -230,75
EBIT 370,30 -199,74 -270,16
Résultat Net 149,80 -252,16 -299,19
Flux de trésorerie disponible 3 186,23 -471,50 -404,00
Dette nette -5 755,45 -3 630,10 -2 698,12
PER 5,50 -3,25 -3,14
Copyright ©2020, S&P Global Market Intelligence. Reproduction of CIQ Estimates in any form is prohibited except with the prior written permission of S&P Global Market Intelligence. CIQ Estimates are not investment advice and a reference to a particular investment or security, a credit rating or any observation concerning a security or investment provided in CIQ Estimates is not a recommendation to buy, sell or hold such investment or security or make any other investment decisions. S&P Global Market Intelligence, its affiliates and their third-party providers (together, “S&P Global”) do not guarantee the accuracy, adequacy, completeness or availability of any information and are not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P GLOBAL DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P Global be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of CIQ Estimates.